Last reviewed · How we verify
NCT03558165: LU-NGS-2
Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
trial testing Oncomine Comprehensive Assay in Lung Cancer Stage IV in 134 participants. Completed in 18 February 2022.
20 August 2020
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 134 |
| Start date | 1 March 2018 |
| Primary completion | 20 August 2020 |
| Estimated completion | 18 February 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Oncomine Comprehensive Assay
Conditions studied
- Lung Cancer Stage IV — all drugs for Lung Cancer Stage IV →
Sponsor
University Health Network, Toronto
Who can join
18 and older, any sex, with Lung Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, publicly funded standard of care testing in Ontario for stage IV lung cancer patients uses individual gene tests to look for mutations in the EGFR and ALK genes. This testing broadens treatment options for patients, however there are other gene mutations with corresponding targeted treatments that are not routinely tested for. This study will evaluate the utility and added value of using a next generation sequencing (NGS) panel, the Oncomine Comprehensive Assay v3, to profile stage IV lung cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Next Generation Sequencing Technology in Lung Cancer Diagnosis.
Cainap C, Balacescu O, Cainap SS, Pop LA. · · 2021 · cited 62× · PMID 34571741 · DOI 10.3390/biology10090864
Verify or expand the search:
- PubMed search for NCT03558165
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer Stage IV
Currently open trials in the same condition.
- NCT06076005 — Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor · recruiting
- NCT03728361 — Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroend · Phase 2 · active not recruiting
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03558165 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 17 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03558165.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing